GI: GERD Flashcards

(64 cards)

1
Q

Types of cells in the gastric gland

A

Mucosal, parietal, chief, endocrine (enterochromaffin like cells, G cells, D cells)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

location & function of mucosal cells

A

Near the top/pit of gastric gland, mucosal cells secrete mucous and bicarb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Location & function of parietal cells

A
  • Isthmus of gastric gland
  • secrete gastric acid and IF
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Parietal cells: resting vs stimulated state

A

Go between resting and stimulated state.

Resting state: tubovesicles in cytoplasm that contain proton pumps. Surface: receptors for gastrin, Ach, histamine

Stimulated state: TVs and PPs fuse to surface. Canaliculus surface area of cell expands to make room for more. HCl and KCl released. Hydrogen and chloride bind –> hydrochloric acid.

K+ is pumped back into cell and process continues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Location & function of chief cells

A

Base of gastric gland

Chief cells secrete gastric lipase and pepsin to break downlipids and proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Location and function of endocrine cells

A

Interspersed through gastric gland

  • Enterochromaffin like cells (ECLs) secrete histamine
  • G cells secrete gastrin
  • D cells secrete somatostatin (the brakes)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

chemical messengers that increase gastric acid secretion

A

Ach, histamine, and gastrin all increase GA secretion.

(Ach released by vagus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

chemical messenger that inhibits gastric acid secretion

A

Somatostatin: binds to ECLs, G cells, and directly to parietal cells to inhibit GA secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Gastric Acid Defenses

A

Lower esophageal sphincter tone

  • Prevents acid reflux into esophagus

Gastric mucous coats the surface of the stomach

  • Traps secreted bicarb
  • Secreted by mucous cells
    • Stimulated by PGs (PGE­­­­1 and PGE2)

Mucous creates gel-like surface. Stimulated by PGs, NSAIDs, decrease PG synthesis – hence ulcer w/overuse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Causes of / risk factors for GERD

A
  • decreased lower esophageal sphincter tone (caffeine, chocolate, spicy foods, etc)
  • decreasedesophageal clearance of gastric fluids
  • decreased saliva production (iatrogenic – meds)
  • Delayed gastric emptying (gastroparesis from diabetes)
  • Obesity
  • Pregnancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How to treat GERD in pregnancy: lifestyle

A

Lifestyle modification before pharm interventions:

  • Smaller meals
  • Avoid eating at bedtime
  • Elevate HOB
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How to treat GERD in pregnancy: pharm

A

Pharm stepwise Tx:

  1. Antacids
  2. H2 antagonists –> Ranitidine (Zantac) has most safety data
  3. PPI (less safety data c/t H2Bs): Lansoprazole (Prevacid) and Pantoprazole (Protonix) have more safety data
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Type of drugs used to treat GERD

A

PPIs, antacids, H2 blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Types of PPIs

A
  • Omeprazole (Prilosec)
  • Esomeprazole (Nexium)
  • Pantoprazole (Protonix)
  • Lansoprazole (Prevacid)
  • Dexlansoprazole (Dexilant)
  • Rabeprazole (Aciphex)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

PPI: MOA

A

Prodrugs absorbed in sm intestines

Travel systematically to parietal cells

Activated by stimulated proton pumps

Irreversible disulfide bonds formed with the proton pump

Must create new proton pumps to secrete gastric acid. Why they are so effective.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

PPI: dosing

A

Counseling: take 15-30min before bfast or biggest meal of day; Dose after dinner for nocturnal symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

PPIs: absorption

A

A: rapid, bioavailability & absorption rate decreased w/food

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

PPIs: half life & duration

A

½ life: 1.5h, 24h duration (irreversible bond)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

PPIs: metabolism

A

M: liver via CYP2C19 and CYP3A4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

PPIs: Excretion

A

E: inactive in urine and feces

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

PPIs: important drug interaction

A

Clopidogred (Plavix) Interaction – prodrug requiring CYP2C19 activation: potential reduce antiPLT activity; avoid PPI or RX protonix or aciphex if necessary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

PPIs: ADRs

A

Prolonged use:

  • decreased vit B12 absorption
  • decreased mg (esp w/diuretics)
  • increased risk bone fractures (decreased Ca absorption) Ca needs acidic environment
  • increased risk C. diff & pneumonia (GA destroys c diff spores, bacteria)

Discontinuation causes rebound acid hypersecretion * -Temporary. some recommend H2B bridge.*

Short term well-tolerated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

PPIs: crush or split tablets?

A

• Do not crush or split tablets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

PPIs vs H2 blockers for esophageal GERD Sx

A

PPIs more efficacious

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
PPIs: which are most effective?
All PPIs equally effective
26
PPIs: what to do if partial response only?
adjust timing to fit Sx, consider BID
27
PPI onset
Takes a few days, Use antacids as bridge
28
PPIs vs H2Bs when maintenance Tx is needed
* Continue PPI if Sx return after Tx, erosive esophagitis, Barrett’s esophagitis * Consider H2 if no erosive esophagitis
29
Omeprazole (Prilosec): available formulations
* Capsule, tablet, suspension * QD, OTC * Available for pedi, 5kg (PPI)
30
Omeprazole (Prilosec): drug interactions
Def not w/Plavix | (PPI)
31
Esomeprazole (Nexium) : formulations
* Capsule, packet, injection * QD, OTC * Available for pedi 1-11yo
32
Pantoprazole (Protonix): formulations
Tablet, packet, injection QD (PPI)
33
Lansoprazole (Prevacid): formulations
* Capsule/ODT, suspension * OTC * Available for pedi 1-11yo (PPI)
34
Dexlansoprazole (Dexilant): formulations
Capsule QD (PPI)
35
Rabeprazole (Aciphex): formulations
* Tablet, sprinkle capsules * QD * Available for pedi 1-11yo
36
Which PPI if must use w/plavix
Pantoprazole (Protonix) or Rabeprazole (Aciphex)
37
PPI w/relatively more safety data in pregnancy
Pantoprazole (Protonix) and Lansoprazole (Prevacid)
38
Most common PPI for pedi, even infants
Lansoprazole (Prevacid)
39
Antacids: MOA
Neutralize GA by reacting w/hydrochloric acid
40
Antacids: special considerations
Consider pt characteristics when Rxing, e.g, no alka seltzer for CHF, RF, low Na+ diet d/t fluid retention
41
Types of antacids
* Sodium Bicarbonate (Alka Seltzer) * Calcium Carbonate (Tums) * Magnesium hydroxide + Aluminum hydroxide (Mylanta)
42
Sodium Bicarbonate (Alka Seltzer): dosing
325 mg 1-4x **daily** prn
43
Calcium Carbonate (Tums): dosing
500-1000 mg **Q2h prn**
44
Magnesium hydroxide + Aluminum hydroxide (Mylanta): dosing
10-20mL (400-800mg aluminum +mg) **4x daily prn**
45
Sodium Bicarbonate (Alka Seltzer): ADRs
Belching, metabolic alkalosis, fluid retention
46
Sodium Bicarbonate (Alka Seltzer)​: forms
NaCl, CO2 and H20
47
Calcium Carbonate (Tums): ADRs
Belching, hypercalcemia, metabolic alkalosis
48
Calcium Carbonate (Tums)​: forms
Forms: CaCl2, CO2 and H20
49
Magnesium hydroxide + Aluminum hydroxide (Mylanta): ADRs
Diarrhea (Mg), Constipation (Al), Aluminum accumulation in CKD Combined to reduce AEs of both
50
Magnesium hydroxide + Aluminum hydroxide (Mylanta): forms & C/Is
* Forms: MgCL and Al2Cl3 and H20 * Not in RF!
51
H2 Blockers: agents
* Cimetidine (Tagamet) * Famotidine (Pepcid) * Ranitidine (Zantac) * Nizatidine (Axid)
52
H2 Blockers: MOA
Acid inhibition via reversible H2 receptor blockade
53
H2 Blockers: absorption
rapid, 1-3h
54
H2 Blockers: 1/2 life & duration
1.1-4h (duration of effect: most 10-12h)
55
H2 Blockers: metabolism
10-35% via liver
56
H2Bs: excretion
parent drug & metabolites in kidneys
57
H2Bs: ADRs
Diarrhea, HA, fatigue, constipation (minor) CNS effects (confusion, hallucinations, delirium) *more in elderly*
58
Cimetidine (Tagamet): formulation & dosing
Tablet or solution Q12h, OTC (H2B)
59
Cimetidine (Tagamet)​: ADRs
H2B adrs + Gynecomastia/impotence (cimetidine) (H2B)
60
Cimetidine (Tagamet): drug interactions
Drug interactions: Cimetidine (CYP2C9, CYP2D6, CYP1A2) - *inhibitor, may increase serum concentration* (H2B)
61
Famotidine (Pepcid): formulations and dosing
* Tablet, suspension, injection * Q12h, OTC * Pedi dosing available
62
Ranitidine (Zantac): formulation and dosing
* Tablet, capsule, syrup, injection * Q12h, OTC * Pedi dosing available
63
Ranitidine (Zantac): pregnancy
Has most safety data in pregnancy of H2Bs
64
Nizatidine (Axid): formulation and dosing
Tablet, capsule, solution Q12h